Skip to main content
. Author manuscript; available in PMC: 2024 Feb 26.
Published in final edited form as: Appl Health Econ Health Policy. 2021 Mar;19(2):155–162. doi: 10.1007/s40258-020-00606-4

Table 2.

Characteristics of cost-utility analyses in the systematic review.

Characteristics Number (n) Percent (%)
ICER (USD per QALY)
< $50,000 186 58.4
$50,000 - $99,999 53 16.7
$100,000 - $149,999 20 6.3
≥ $150000 58 18.6
Cost-effectiveness threshold referenced
Single 238 75.1
Multiplea 43 13.6
No threshold referenced 36 11.4

ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.

a

Category includes multiple and range of cost-effectiveness thresholds.